Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Rabies Immune Plasma Booster Study

This study has been completed.
CSL Plasma
Information provided by (Responsible Party):
CSL Behring Identifier:
First received: February 4, 2010
Last updated: September 3, 2015
Last verified: September 2015

Rabies immune globulin is a product that is lifesaving to unvaccinated individuals exposed to the rabies virus. Rabies immune globulin is made from plasma from immune donors. Currently the only practical method to obtain this plasma is to immunize normal volunteer Source Plasma donors and collect their plasma while titers are adequate. The use of rabies vaccine for immunization of normal Source Plasma donors is currently limited to a level that, while protective for the individual, is unsuitable for production of rabies immune globulin.

The objective of this study is to obtain efficacy and safety data regarding the rabies boostering program to demonstrate that:

  1. Rabies immune plasma production can be substantially increased by giving booster doses to previously immunized donors whose titers are below 10.0 IU/mL.
  2. It is safe for normal Source Plasma donors to receive booster doses of rabies vaccine on a regular basis.

This study utilizes two rabies vaccines approved by the FDA, Imovax® (Sanofi-Pasteur) and RabAvert® (Novartis).

Condition Intervention Phase
Biological: Rabies Vaccine (RabAvert)
Biological: Rabies Vaccine (Imovax)
Phase 4

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Rabies Immune Plasma Booster Program - A Clinical Study Conducted as an Investigational New Drug Study

Resource links provided by NLM:

Further study details as provided by CSL Behring:

Primary Outcome Measures:
  • Geometric mean titer (GMT) for rabies plasma donations received after booster injections [ Time Frame: 30-day intervals for the duration of the study (up to 2 years) ]

Secondary Outcome Measures:
  • Adverse Event Reaction Rate [ Time Frame: 30-35 days after each injection ]

Enrollment: 491
Study Start Date: January 2009
Study Completion Date: May 2010
Primary Completion Date: May 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
RabAvert Biological: Rabies Vaccine (RabAvert)
The initial booster immunization is given on Day 1; subsequent booster immunizations will be administered if the donor's titers fall below 10 IU/mL. A maximum of 4 booster immunizations may be administered over the 2 year study period.
Other Name: Rabipur
Imovax Biological: Rabies Vaccine (Imovax)
The initial booster immunization is given on Day 1; subsequent booster immunizations will be administered if the donor's titers fall below 10 IU/mL. A maximum of 4 booster immunizations may be administered over the 2 year study period.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Source Plasma Donors. Donors must meet FDA and CSL Plasma requirements to be Source Plasma Donors. Donors had previously participated in CSL's rabies vaccine immunization program.

Inclusion Criteria:

  • Meet requirements for Source Plasma donors
  • Completed initial series of rabies antibody injections with no serious adverse events for at least 90 days prior to enrollment
  • Compliance with program requirements
  • Signed informed consent

Exclusion Criteria:

  • Failure to meet requirements to be Source Plasma donor
  • Non-compliance with the program
  • Experience a serious adverse reaction
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01063140

United States, Arizona
CSL Donor Plasma Center
Tempe, Arizona, United States, 85282
United States, Illinois
CSL Donor Plasma Center
Rock Island, Illinois, United States, 61201
United States, Michigan
CSL Donor Plasma Center
Oak Park, Michigan, United States, 48237
United States, Minnesota
CSL Donor Plasma Center
St. Paul, Minnesota, United States, 55104
United States, Ohio
CSL Donor Plasma Center
Cleveland, Ohio, United States, 44109
CSL Donor Plasma Center
Springfield, Ohio, United States, 45503
United States, Oklahoma
CSL Donor Plasma Center
Oklahoma City, Oklahoma, United States, 73103
United States, Oregon
CSL Donor Plasma Center
Medord, Oregon, United States, 97501
United States, Tennessee
CSL Donor Plasma Center
Knoxville, Tennessee, United States, 37916
United States, Utah
CSL Donor Plasma Center
Salt Lake City, Utah, United States, 84115
Sponsors and Collaborators
CSL Behring
CSL Plasma
Principal Investigator: Toby L. Simon, MD CSL Plasma
  More Information

Additional Information:
Responsible Party: CSL Behring Identifier: NCT01063140     History of Changes
Other Study ID Numbers: ZLB 1
Study First Received: February 4, 2010
Last Updated: September 3, 2015

Keywords provided by CSL Behring:
Rabies Immune Globulin
Source Plasma Donors
Booster Immunization

Additional relevant MeSH terms:
Rhabdoviridae Infections
Mononegavirales Infections
RNA Virus Infections
Virus Diseases
Immunologic Factors
Physiological Effects of Drugs processed this record on May 25, 2017